Breaking News Instant updates and real-time market news.

TROV

Trovagene

$4.15

0.34 (8.92%)

13:11
04/01/19
04/01
13:11
04/01/19
13:11

Trovagene jumps after reporting results from Acute Myeloid Leukemia trial

Shares of TrovaGene are up 86c, or 23%, to $4.61 following the company's report of new data from its ongoing Phase 1b/2 study evaluating onvansertib in combination with standard-of-care chemotherapy in Acute Myeloid Leukemia, or AML. Objective response rate has been observed at last 3 highest dose levels of onvansertib with 5 of 19 evaluable patients achieving a complete response, the company reported.

  • 01

    Apr

TROV Trovagene
$4.15

0.34 (8.92%)

06/18/18
MAXM
06/18/18
UPGRADE
Target $3
MAXM
Buy
Trovagene upgraded to Buy at Maxim on positive PCM-075 news
As reported earlier Maxim analyst Jason McCarthy upgraded Trovagene to Buy from Hold with a price target of $3, citing the positive news from the company's lead drug candidate PCM-075 as well as its completion of a capital raise. The analyst notes that Trovagene's balance sheet now gives it a run rate into the second half of 2019 while the PCM-075 studies progress toward their next set of catalysts. Given the suspension of the financing overhang, McCarthy says the company's potential justifies a more constructive stance.
06/18/18
06/18/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Francesca's (FRAN) upgraded to Buy from Neutral at B. Riley FBR with analyst Susan Anderson saying she has increased confidence in the company's turnaround following meetings with management. 2. Chevron (CVX) upgraded to Outperform from Market Perform at Raymond James with analyst Pavel Molchanov saying Chevron offers relatively more leverage than most peers to higher oil prices, which should reach cyclical highs over the next 6 to 12 months, while low WTI exposure maximizes earnings and free cash flow generation. 3. Trovagene (TROV) upgraded to Buy from Hold at Maxim with analyst Jason McCarthy citing the positive news from the company's lead drug candidate PCM-075 as well as its completion of a capital raise. 4. RBS (RBS) upgraded to Buy from Hold at Investec. 5. Teva (TEVA) upgraded to Market Perform from Underperform at Wells Fargo with analyst David Maris citing a "positive meeting" with Teva's CEO Kundefinedre Schultz and CFO Mike McClellan in Israel. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/07/19
NBLE
01/07/19
INITIATION
Target $5.2
NBLE
Outperform
Trovagene initiated with an Outperform at Noble Financial
Noble Financial analyst Ahu Demir initiated Trovagene with an Outperform rating and $5.20 price target, stating that investors remain skeptical of PLK1 targeting but he foresees upside potential and likes TrovaGene's Onvansertib. He believes further data will be valuable to demonstrate anti-tumor activity and the safety profile of Onvansertib, Demir tells investors.
03/01/19
MAXM
03/01/19
NO CHANGE
Target $8
MAXM
Buy
Trovagene price target lowered to $8 from $18 at Maxim
Maxim analyst Jason McCarthy lowered his post-split price target for Trovagene to $8 from $18, which reflects dilution associated with future capital raises. The analyst keeps a Buy rating on the shares ahead of a "busy" American Association for Cancer Research annual meeting for the company in late March. Trovagene now has three funded clinical trials with Onvansertib, and as updates are provided in 2019, they should, if positive, support a higher valuation, McCarthy tells investors in a research note.

TODAY'S FREE FLY STORIES

RHHBY

Roche

$0.00

(0.00%)

06:42
10/16/19
10/16
06:42
10/16/19
06:42
Earnings
Roche raises FY19 sales outlook to high-single digit range »

Sales are now expected to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

  • 06

    Nov

AUPH

Aurinia Pharmaceuticals

$4.67

0.79 (20.36%)

06:42
10/16/19
10/16
06:42
10/16/19
06:42
Hot Stocks
Aurinia Pharmaceuticals completes at-the-market share sale »

Aurinia Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

06:41
10/16/19
10/16
06:41
10/16/19
06:41
Earnings
Roche reports nine months group sales CHF 46.07B vs. CHF 42.08B last year »

Reports pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

  • 06

    Nov

AUPH

Aurinia Pharmaceuticals

$4.67

0.79 (20.36%)

06:40
10/16/19
10/16
06:40
10/16/19
06:40
Hot Stocks
Aurinia reports last patient study visit in Aurora Phase 3 lupus study »

Aurinia Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCON

Superconductor Technologies

$0.23

-0.0266 (-10.17%)

06:40
10/16/19
10/16
06:40
10/16/19
06:40
Hot Stocks
Superconductor Technologies awarded new U.S. patent »

Superconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVFM

Evofem

$5.01

-0.065 (-1.28%)

06:39
10/16/19
10/16
06:39
10/16/19
06:39
Initiation
Evofem initiated  »

Evofem assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASML

ASML

$267.56

5.73 (2.19%)

06:37
10/16/19
10/16
06:37
10/16/19
06:37
Hot Stocks
Breaking Hot Stocks news story on ASML »

ASML CEO Peter Wennink…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 19

    Nov

ASML

ASML

$267.56

5.73 (2.19%)

06:37
10/16/19
10/16
06:37
10/16/19
06:37
Earnings
ASML sees Q4 net sales around EUR3.9B »

ASML sees Q4 gross margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 19

    Nov

FSCT

ForeScout

$26.13

0.56 (2.19%)

06:36
10/16/19
10/16
06:36
10/16/19
06:36
Recommendations
ForeScout analyst commentary  »

ForeScout price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 12

    Dec

ASML

ASML

$267.56

5.73 (2.19%)

06:36
10/16/19
10/16
06:36
10/16/19
06:36
Earnings
ASML reports Q3 EPS EUR1.49 vs. EUR1.13 in Q2 »

Reports Q3 net sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 19

    Nov

FHN

First Horizon

$16.13

0.22 (1.38%)

06:36
10/16/19
10/16
06:36
10/16/19
06:36
Earnings
First Horizon reports Q3 adjusted EPS 43c, consensus 42c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 07

    Nov

BK

BNY Mellon

$44.37

0.47 (1.07%)

06:33
10/16/19
10/16
06:33
10/16/19
06:33
Earnings
BNY Mellon reports Q3 EPS $1.07, consensus 99c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

BLDR

Builders FirstSource

$21.54

0.96 (4.66%)

06:33
10/16/19
10/16
06:33
10/16/19
06:33
Upgrade
Builders FirstSource rating change  »

Builders FirstSource…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 13

    Nov

  • 14

    Nov

NEPT

Neptune Wellness

$3.46

0.135 (4.06%)

06:33
10/16/19
10/16
06:33
10/16/19
06:33
Hot Stocks
Neptune Wellness announces Sherbrooke facility to use new cold ethanol equipment »

Neptune Wellness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

BMCH

BMC Stock Holdings

$26.15

0.94 (3.73%)

06:33
10/16/19
10/16
06:33
10/16/19
06:33
Upgrade
BMC Stock Holdings rating change  »

BMC Stock Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 13

    Nov

ALXN

Alexion

$104.85

3.455 (3.41%)

, ACHN

Achillion

$3.66

0.115 (3.25%)

06:33
10/16/19
10/16
06:33
10/16/19
06:33
Hot Stocks
Alexion to acquire Achillion for $6.30 per share in cash »

Alexion Pharmaceuticals…

ALXN

Alexion

$104.85

3.455 (3.41%)

ACHN

Achillion

$3.66

0.115 (3.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

AVGO

Broadcom

$290.46

8.81 (3.13%)

06:32
10/16/19
10/16
06:32
10/16/19
06:32
Hot Stocks
Broadcom ordered by EU to halt allegedly anticompetitive contract practices »

The European Commission…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNX

Knight-Swift

$35.68

-0.365 (-1.01%)

06:31
10/16/19
10/16
06:31
10/16/19
06:31
Recommendations
Knight-Swift analyst commentary  »

Knight-Swift should rally…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

ALXN

Alexion

$104.85

3.455 (3.41%)

, ACHN

Achillion

$3.66

0.115 (3.25%)

06:31
10/16/19
10/16
06:31
10/16/19
06:31
Hot Stocks
Breaking Hot Stocks news story on Alexion, Achillion »

Alexion to acquire…

ALXN

Alexion

$104.85

3.455 (3.41%)

ACHN

Achillion

$3.66

0.115 (3.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

AMZN

Amazon.com

$1,768.70

31.65 (1.82%)

, ORCL

Oracle

$56.35

-0.1 (-0.18%)

06:29
10/16/19
10/16
06:29
10/16/19
06:29
Hot Stocks
Amazon says consumer business turns off final Oracle database »

Amazon (AMZN) said in a…

AMZN

Amazon.com

$1,768.70

31.65 (1.82%)

ORCL

Oracle

$56.35

-0.1 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 21

    Nov

BTI

British American Tobacco

$34.60

0.245 (0.71%)

, MO

Altria Group

$43.43

0.72 (1.69%)

06:27
10/16/19
10/16
06:27
10/16/19
06:27
Periodicals
Congress probes whether e-cig manufacturers paid for spam bots, WSJ reports »

Congress has launched an…

BTI

British American Tobacco

$34.60

0.245 (0.71%)

MO

Altria Group

$43.43

0.72 (1.69%)

IMBBY

Imperial Brands

$0.00

(0.00%)

PM

Philip Morris

$78.32

0.28 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 12

    Nov

RYAM

Rayonier Advanced Materials

$4.70

0.21 (4.68%)

06:27
10/16/19
10/16
06:27
10/16/19
06:27
Downgrade
Rayonier Advanced Materials rating change  »

Rayonier Advanced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CP

Canadian Pacific

$218.42

3.27 (1.52%)

06:26
10/16/19
10/16
06:26
10/16/19
06:26
Downgrade
Canadian Pacific rating change  »

Canadian Pacific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

RYTM

Rhythm Pharmaceuticals

$20.90

0.52 (2.55%)

06:24
10/16/19
10/16
06:24
10/16/19
06:24
Syndicate
Rhythm Pharmaceuticals 8.11M share Spot Secondary priced at $18.50 »

The deal priced inside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

PRQR

ProQR Therapeutics

$6.21

-0.09 (-1.43%)

06:23
10/16/19
10/16
06:23
10/16/19
06:23
Syndicate
ProQR Therapeutics 9.091M share Spot Secondary priced at $5.50 »

Citi and Evercore ISI…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.